Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 6/20 | 0.62 |
| ▸ | ANO1 | Q5XXA6 | 10/20 | 0.50 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.45 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26186535 | 0.98 | P2RX4 (0.61) | P2RX4ANO1RORANR2E1 | |
| SCHEMBL30285710 | 0.98 | P2RX4 (0.61) | P2RX4ANO1RORANR2E1 | |
| SCHEMBL26186569 | 0.95 | P2RX4 (0.63) | P2RX4ANO1RORANR2E1KCNJ5 | |
| SCHEMBL29005473 | 0.95 | P2RX4 (0.62) | P2RX4ANO1RORANR2E1KCNJ5 | |
| SCHEMBL30285805 | 0.94 | P2RX4 (0.61) | P2RX4ANO1RORANR2E1KCNJ5 | |
| SCHEMBL26186539 | 0.94 | P2RX4 (0.61) | P2RX4ANO1RORANR2E1KCNJ5 | |
| SCHEMBL25371065 | 0.93 | P2RX4 (0.69) | P2RX4ANO1RORANR2E1KCNJ5 | |
| SCHEMBL25370426 | 0.92 | P2RX4 (0.62) | P2RX4ANO1 | |
| SCHEMBL26186570 | 0.91 | P2RX4 (0.58) | P2RX4ANO1 | |
| SCHEMBL29005442 | 0.91 | P2RX4 (0.53) | P2RX4ANO1RORANR2E1KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | claimed |